Unfortunately, cancer is a disease that affects more and more people. But, fortunately, this health problem has more and more treatments and positive results. Advances in medicine are increasingly important and help patients improve and recover. The treatments are also…
Unfortunately, cancer is a disease that affects more and more people. But, fortunately, this health problem has more and more treatments and positive results. Advances in medicine are increasingly important and help patients improve and recover. Treatments are also becoming more specific and, therefore, the market value of these medications is also growing.
By 2030, the market value of cancer vaccines is expected to reach $13.4 billion.
Looking to 2030, the consulting firm Next Move Strategy Consulting has calculated that the market value of vaccines created to combat cancer could reach 13.4 billion US dollars.
This value more than doubles the value reached last year 2022, where the figure of 5.74 million dollars was reached. In total, the percentage increase in just 8 years of difference would amount to 133.45%. The consulting firm predicts that the increase will be progressive in the coming years until it exceeds 13 million dollars in 2030.
Technological advances will favor the increase in the market value of cancer vaccines.
The main market niches for vaccines are more or less evenly distributed between cervical cancer, prostate cancer and other cancers. Which means that these three blocks are equally important when it comes to researching and creating a new vaccine.
Being able to detect cancer early will be decisive for the growth of the market value of vaccines. Thanks to technological advances, it is becoming easier to detect cancers such as breast, lung or liver. Being aware from the first moment of the presence of this disease in the body will allow treatment to be simpler than when it is in a more advanced stage. That is why vaccines will become so important in eliminating this disease from the body.
Europe encouraged the increase in the market value of these vaccines.
In Europe, about 12 million people with cancer survived in 2021, 300 thousand of them were children. This is due, among other factors, to the intervention of these vaccines. The presence of local manufacturers is facilitating new strategies to combat this disease with new product launches.
However, North America is the leader in this market and is expected to remain so during this period. Among other aspects, the human papillomavirus vaccine was approved in the United States, which prevents cervical cancer. In addition, the region is seeing its demand for cancer vaccines increase due to the increase in alcohol and tobacco consumption. These and other causes caused around 1.9 million new cases of cancer and more than 608 thousand deaths in the United States in 2021.
KEEP READING
2023-11-27 07:40:54
#market #cancer #vaccines #doubles
